Gene and cell therapy using cell fusion technology
US-11998617-B2 · Jun 4, 2024 · US
Ameliorating nervous systems disorders
US11564949B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11564949-B2 |
| Application number | US-202016993914-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 14, 2020 |
| Priority date | May 6, 2008 |
| Publication date | Jan 31, 2023 |
| Grant date | Jan 31, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for the treatment of a mammal with a chronic pain disorder associated with a neurological condition, comprising: depositing medial ganglionic eminence (MGE) precursor cells at desired delivery sites in the nervous system of the mammal, and wherein the MGE precursor cells are genetically modified to express an exogenous protein. 2. The method of claim 1 , wherein the exogenous protein allows tracking of the MGE precursor cells following transplantation or wherein the exogenous protein is a neurotransmitter producing enzyme, a neurotrophin, a neural promoting growth factor, a neural inhibitory growth factor, or a neuropoietic cytokine. 3. The method of claim 1 , wherein the exogenous protein is a telomerase. 4. The method of claim 1 , further comprising assessing an improvement of the symptoms of the chronic pain disorder in the treated mammal. 5. The method of claim 1 , wherein the neurological condition comprises nerve injury. 6. The method of claim 1 , wherein the chronic pain is neuropathic pain resulting from a spinal cord injury. 7. The method of claim 1 , wherein the MGE precursor cells are deposited by injection. 8. The method of claim 1 , wherein the MGE precursor cells are deposited into the peripheral nervous system. 9. The method of claim 1 , wherein the mammal does not require immunosuppressive therapy following treatment. 10. The method of claim 1 , wherein the MGE precursor cells are deposited into the brain or spinal cord. 11. A method for the treatment of a mammal with a chronic pain disorder associated with a neurological condition, comprising: depositing medial ganglionic eminence (MGE) precursor cells at desired delivery sites in the nervous system of the mammal, and wherein the MGE precursor cells are genetically modified to modulate expression of a protein associated with neural function, wherein the protein is a neurotransmitter producing enzyme, a neurotrophin, a neural promoting growth factor, a neural inhibitory growth factor, a neuropoietic cytokine, or a telomerase. 12. The method of claim 11 , wherein the protein is a telomerase. 13. The method of claim 11 , wherein the protein is a neurotransmitter producing enzyme, a neurotrophin, a neural promoting growth factor, a neural inhibitory growth factor, or a neuropoietic cytokine. 14. The method of claim 11 , further comprising assessing an improvement of the symptoms of the chronic pain disorder in the treated mammal. 15. The method of claim 11 , wherein the neurological condition comprises nerve injury. 16. The method of claim 11 , wherein the chronic pain is neuropathic pain resulting from a spinal cord injury. 17. The method of claim 11 , wherein the MGE precursor cells are deposited by injection. 18. The method of claim 11 , wherein the MGE precursor cells are deposited into the peripheral nervous system. 19. The method of claim 11 , wherein the mammal does not require immunosuppressive therapy following treatment. 20. The method of claim 11 , wherein the MGE precursor cells are deposited into the brain or spinal cord.
Assignees
Inventors
Classifications
Pain, e.g. neuropathic pain, psychogenic pain · CPC title
Brain, e.g. brain implants; Spinal cord · CPC title
from embryonic cells · CPC title
Cells of the nervous system · CPC title
- A61K35/30Primary
Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11564949B2 cover?
- The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K35/30. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).